Fig. 1From: Evaluation of the vascular protective effects of new oral anticoagulants in high-risk patients with atrial fibrillation (PREFER-AF): study protocol for a randomized controlled trialPREFER-AF trial flow diagram. Participants will receive new oral anticoagulant (NOAC) or vitamin K (vitK)-antagonist treatment according to the assigned sequence; then, endothelial function and clinical events will be assessedBack to article page